News on BTG from BioPortfolio.com http://www.BioPortfolio.com Consolidated BTG news from BioPortfolio.com Wed, 10 Feb 2010 16:09:34 GMT en BTG gets Swissmedic nod for antidote DigiFab to treat digitalis intoxicationhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4027514&HITNO=0&MSIZE=14&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=BTG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4027514&THISHREF=http://c.moreover.com/click/here.pl%3fz2532220360%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4027514&HITNO=0&MSIZE=14&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=BTG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4027514&THISHREF=http://c.moreover.com/click/here.pl%3fz2532220360%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmaBiz: BTGs Treatment for Digitalis Overdose Sanctioned in Switzerlandhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4018671&HITNO=1&MSIZE=14&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=BTG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4018671&THISHREF=http://c.moreover.com/click/here.pl%3fz2525872946%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4018671&HITNO=1&MSIZE=14&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=BTG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4018671&THISHREF=http://c.moreover.com/click/here.pl%3fz2525872946%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGenetic Engineering News: BTG Receives First European Regulatory Approval for DigiFabhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4020740&HITNO=2&MSIZE=14&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=BTG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4020740&THISHREF=http://c.moreover.com/click/here.pl%3fz2526986519%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4020740&HITNO=2&MSIZE=14&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=BTG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4020740&THISHREF=http://c.moreover.com/click/here.pl%3fz2526986519%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMDLinx: BTG Gets First European Regulatory Approval for DigiFabhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4017506&HITNO=3&MSIZE=14&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=BTG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4017506&THISHREF=http://c.moreover.com/click/here.pl%3fz2525172062%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4017506&HITNO=3&MSIZE=14&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=BTG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4017506&THISHREF=http://c.moreover.com/click/here.pl%3fz2525172062%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFDA News: Research and Markets: BioPharma Productivity Crisis, What BioPharma Productivity Crisis?http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4005301&HITNO=4&MSIZE=14&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=BTG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4005301&THISHREF=http://c.moreover.com/click/here.pl%3fz2520314064%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4005301&HITNO=4&MSIZE=14&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=BTG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4005301&THISHREF=http://c.moreover.com/click/here.pl%3fz2520314064%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: BTG plc: Interim Management Statementhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3950193&HITNO=5&MSIZE=14&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=BTG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3950193&THISHREF=http://c.moreover.com/click/here.pl%3fz2489511832%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3950193&HITNO=5&MSIZE=14&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=BTG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3950193&THISHREF=http://c.moreover.com/click/here.pl%3fz2489511832%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmiWeb: BTG Commences Phase IIa Study of Pleneva„ for Multiple Sclerosishttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3950188&HITNO=6&MSIZE=14&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=BTG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3950188&THISHREF=http://c.moreover.com/click/here.pl%3fz2489511561%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3950188&HITNO=6&MSIZE=14&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=BTG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3950188&THISHREF=http://c.moreover.com/click/here.pl%3fz2489511561%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmiWeb: BTG Commences Phase IIa Study of Pleneva for Multiple Sclerosishttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3948152&HITNO=7&MSIZE=14&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=BTG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3948152&THISHREF=http://c.moreover.com/click/here.pl%3fz2488429483%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3948152&HITNO=7&MSIZE=14&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=BTG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3948152&THISHREF=http://c.moreover.com/click/here.pl%3fz2488429483%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMDLinx: BTG plc: Interim Management Statementhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3948153&HITNO=8&MSIZE=14&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=BTG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3948153&THISHREF=http://c.moreover.com/click/here.pl%3fz2488429537%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3948153&HITNO=8&MSIZE=14&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=BTG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3948153&THISHREF=http://c.moreover.com/click/here.pl%3fz2488429537%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMDLinx: BTG Initiates Phase IIa Pleneva Studyhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3941633&HITNO=9&MSIZE=14&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=BTG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3941633&THISHREF=http://c.moreover.com/click/here.pl%3fz2485519936%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3941633&HITNO=9&MSIZE=14&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=BTG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3941633&THISHREF=http://c.moreover.com/click/here.pl%3fz2485519936%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmaceutical Business Review: BTG licenses drug delivery system to Allerganhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3873956&HITNO=10&MSIZE=14&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=BTG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3873956&THISHREF=http://c.moreover.com/click/here.pl%3fz2450233938%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3873956&HITNO=10&MSIZE=14&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=BTG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3873956&THISHREF=http://c.moreover.com/click/here.pl%3fz2450233938%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comModern Medicine: BTG licenses drug delivery system to Allergan for eye diseaseshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3868865&HITNO=11&MSIZE=14&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=BTG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3868865&THISHREF=http://c.moreover.com/click/here.pl%3fz2447925077%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3868865&HITNO=11&MSIZE=14&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=BTG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3868865&THISHREF=http://c.moreover.com/click/here.pl%3fz2447925077%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comModern Medicine: BTG licenses drug delivery system to Allergan for use in eye diseaseshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3863019&HITNO=12&MSIZE=14&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=BTG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3863019&THISHREF=http://c.moreover.com/click/here.pl%3fz2445319796%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3863019&HITNO=12&MSIZE=14&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=BTG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3863019&THISHREF=http://c.moreover.com/click/here.pl%3fz2445319796%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comModern Medicine: Oxford Biomedica PLC : Management and Board Changeshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3856799&HITNO=13&MSIZE=14&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=BTG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3856799&THISHREF=http://c.moreover.com/click/here.pl%3fz2442601596%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3856799&HITNO=13&MSIZE=14&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=BTG&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3856799&THISHREF=http://c.moreover.com/click/here.pl%3fz2442601596%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comInvestegate: